Munich, 16 August 2019
Affiliates of Equistone Partners Europe are acquiring a majority stake in the oncology whole-sale of Omnicare Group (“Omnicare”). Seller of the shares is the current consortium of share-holders who retains a significant stake. The management team around the managing director Oliver Tamimi will continue to take responsibility for the company and will participate sub-stantially in the transaction. The acquisition is still subject to approval by the relevant antitrust authorities. The transaction is expected to close in the fourth quarter of 2019. honert + partner legally advises the Omnicare management on the transaction.
Omnicare was founded in 2002 as a specialist pharmaceutical wholesaler for outpatient onco-logical care. Today, the group is the market leader in the sale of oncological finished pharma-ceuticals, on the basis of which pharmacies produce patient-specific cancer medication. In addition to supplying finished pharmaceuticals, Omnicare has been developing important ser-vices for highly specialized pharmacies and medical practices for quality assurance, for moni-toring cleanroom hygiene and for training and further education of specialist staff since 2012. In 2018, the wholesaler established the Deutsche Onkologische Netzwerk (German Oncologi-cal Network), a network of leading practices in the field of cancer therapy. The company has systematically developed into a platform for outpatient oncological care and is active through-out Germany. For Oliver Tamimi (shareholder and managing director), Equistone Partners Europe is a “reliable and well-funded partner with whose support it is intended to continuously improve the local and outpatient care of cancer patients in Germany”.
The Omnicare management was legally advised by the following Munich team at honert + partner:
honert + partner (Munich): Dr. Jochen Neumayer (lead management, Corporate Law, M&A, Tax Law), Prof. Dr. Thomas Grädler (Corporate Law, M&A, Tax Law); Andrea Beilborn (Corporate Law, M&A)